Topical CoQ10 Formulation for Chronic EB Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no specific proven treatment for Epidermolysis Bullosa (EB), a group of genetically determined skin fragility disorders characterized by blistering and chronic wounds that are prone to infections and impair quality of life, with standard wound care being ineffective due to genetic mutations affecting structural and functional proteins.
Innovation Solution
Topical application of Coenzyme Q10 (CoQ10) to alter the expression of structural and functional proteins, promoting the transition from inflammation to proliferation and remodeling stages in wound healing, reducing blister and wound size, and improving skin integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for EB, then basic wound care is provided, but chronic inflammation persists and healing is delayed
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters of the treatment - specifically using CoQ10 at concentrations of 0.1-10% w/v in combination with specific excipients like propylene glycol and ethanol. This chemical parameter modification enables the wound to transition from chronic inflammation to active healing, resolving the contradiction between healing effectiveness and time duration.
Solution Approach 2:
CoQ10 acts as an intermediary substance that mediates the transition from chronic inflammation to wound healing. The patent demonstrates that CoQ10 supplementation serves as a bridging mechanism between the stalled inflammatory phase and the proliferative healing phase, enabling progression through the healing cascade that conventional treatments fail to achieve.
2Reliability
If topical CoQ10 is applied to promote protein expression and wound healing, then blister size reduces and skin integrity improves, but the complexity of treatment increases
Solution Approach 1:
The patent employs composite materials by formulating CoQ10 with specific excipients including propylene glycol, ethanol, and water in defined ratios. This composite formulation approach enhances the stability, solubility, and topical delivery efficiency of CoQ10, achieving improved skin integrity while managing formulation complexity through systematic composition design.
3Strength
If CoQ10 is used to alter protein expression in skin, then structural and functional proteins increase, but the mechanism complexity increases
Solution Approach 1:
The patent applies self-service by utilizing CoQ10's natural role in mitochondrial function and cellular energy production. Rather than introducing complex external signaling pathways, the treatment leverages the body's endogenous CoQ10 metabolism and protein synthesis mechanisms to upregulate structural proteins like collagen and elastin, achieving improved skin strength through the body's own biological systems.
Data Source
AI summary
The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.